Ensera, American Injectables team up on fill-finish and commercialization

Ensera has formed a strategic alliance with Florida-based American Injectables to create a more integrated path from aseptic fill-finish to device assembly, packaging and serialization for sterile injectable drugs. The companies say the deal is designed to help pharma firms move faster into the North American market and strengthen supply-chain resilience.

Why it matters: - The alliance gives drugmakers a single Florida-based route from fill-finish through final assembly, secondary packaging and serialization. - The setup is aimed at companies that need faster commercialization and a more flexible entry point into the North American market. - The partnership also fits a broader industry push to regionalize supply chains and reduce risk in essential medicine delivery.

What happened: - Ensera announced a strategic alliance with American Injectables on Sept. 8, 2026. - Ensera is a contract design, manufacturing and packaging company serving pharmaceutical and medical device customers. - American Injectables is a Florida-based CDMO focused on the fill-finish of sterile injectable drugs. - Both companies operate manufacturing facilities in Central Florida that are only miles apart.

The details: - The combined offering is intended to support small- to medium-scale production with speed and precision. - The alliance is built to connect aseptic fill-finish with final device assembly, secondary packaging and serialization. - Ensera completed a major upgrade to its Florida site in April 2025, expanding services for drug device manufacturing, final assembly and secondary packaging of combination products. - American Injectables recently completed a major expansion of its FDA-registered and inspected Florida facility, adding filling capacity. - Ensera says the alliance is part of its expanding pharmaceutical manufacturing operations in Florida. - American Injectables says the partnership extends its vision across the supply chain and creates a one-stop shop for companies developing sterile injectable and combination products. - Ensera’s website is the company's website. - American Injectables’ website is the company's website.

Between the lines: - The deal is as much about geography as capability. Two nearby plants can mean fewer handoffs and less friction between manufacturing steps. - Ensera has been building a broader network of partnerships. The company recently announced a fill-finish partnership with Argonaut and has assembly partnerships with Ypsomed, SHL Medical and BD. - Those alliances are intended to reduce handovers, improve accountability and smooth the move from development to commercialization.

What's next: - The companies will market the combined offering to pharma firms developing sterile injectable and combination products. - The Florida footprint gives the partnership a regional advantage for U.S.-focused programs. - Ensera and American Injectables are positioning the alliance as a scalable platform for future commercial and clinical manufacturing demand. - Media contacts listed in the release are Josh Lowth for Ensera and Jennifer Kline for American Injectables.

The bottom line: - Ensera and American Injectables are trying to remove complexity from the injectable drug supply chain by tying fill-finish, assembly and packaging into one Florida-based workflow.